BioCentury | Jan 21, 2021
Product Development

The evolving zeitgeist of COVID-19 testing

...The shift coincides with the maturation of liquid biopsy...
BioCentury | Jan 20, 2021
Politics, Policy & Law

Biden’s science team & early cancer detection: a BioCentury podcast

...in the new administration. They then take a look at the newest entrants to the liquid biopsy...
...Inc. and Earli Inc. are standing out from the crowd of companies in the maturing liquid biopsy...
BioCentury | Jan 15, 2021
Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

...partners were not disclosed.The same day, Guardant announced the launch of Guardant Reveal, the first liquid biopsy...
...FDA-approved test that detects methylated SEPT9.TARGETSSEPT9 -Septin 9 Karen Tkach Tuzman Grail Inc. Guardant Health Inc. Freenome Inc. early cancer detection liquid biopsy earli delfi...
BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

...Assistant Editor Paige’s $100 million series C suggests investor enthusiasm for cancer diagnostics extends beyond liquid biopsy...
...versus normal cells.The large venture rounds come after several high-profile M&A events and fund-raisings for liquid biopsy...
BioCentury | Jan 12, 2021
Deals

Jan. 11 Quick Takes: Inmagene gains options to four Chi-Med immunology programs; plus Zai-Turning Point, Mirati-Resolution, GSK-Eligo, Biogen-Apple, Adaptive-AZ and more

...to Turning Point’s lead program repotrectinib for the same up front sum.Mirati to use Resolution’s liquid biopsy...
...patientsMirati Therapeutics Inc. (NASDAQ:MRTX) said it partnered with Resolution Bioscience Inc. to use its ctDx liquid biopsy...
BioCentury | Nov 19, 2020
Management Tracks

CStone’s Yeh joins Abbisko as CFO; plus moves at Ziopharm, Permira, Imara, Inivata, Topas and Arch

...global head of cystic fibrosis regulatory strategy and commercial regulatory affairs at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX).Liquid biopsy...
BioCentury | Nov 18, 2020
Emerging Company Profile

InterVenn: liquid biopsy diagnostics based on glycoproteins

...to launch its first diagnostic —a liquid biopsy...
...approaches.InterVenn hasn’t had to compete with DNA-based liquid biopsy...
...reported interim data from VOCAL showing the liquid biopsy...
BioCentury | Nov 10, 2020
Regulation

Label expansions coming at a rapid clip for Foundation’s blood-based companion cancer diagnostic

...three weeks, FDA has added four companion diagnostic indications to the label of Foundation Medicine’s liquid biopsy...
BioCentury | Oct 28, 2020
Deals

Thrive takeout could herald consolidation trend for early cancer detection companies

...24, its shares rose 27% to $94.04  after a presentation revealed it was developing its own liquid biopsy...
BioCentury | Oct 8, 2020
Product Development

Mapping opportunities for China’s early cancer detection boom

...willingness to pay out of pocket. At least three Chinese companies have already begun offering liquid biopsy...
...healthcare expenditure,” Decheng Capital’s Victor Tong told BioCentury.The country set a precedent for adoption of liquid biopsy-based...
...these companies are now branching into early detection.One of the first Asian companies built around liquid biopsy...
Items per page:
1 - 10 of 185
BioCentury | Jan 21, 2021
Product Development

The evolving zeitgeist of COVID-19 testing

...The shift coincides with the maturation of liquid biopsy...
BioCentury | Jan 20, 2021
Politics, Policy & Law

Biden’s science team & early cancer detection: a BioCentury podcast

...in the new administration. They then take a look at the newest entrants to the liquid biopsy...
...Inc. and Earli Inc. are standing out from the crowd of companies in the maturing liquid biopsy...
BioCentury | Jan 15, 2021
Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

...partners were not disclosed.The same day, Guardant announced the launch of Guardant Reveal, the first liquid biopsy...
...FDA-approved test that detects methylated SEPT9.TARGETSSEPT9 -Septin 9 Karen Tkach Tuzman Grail Inc. Guardant Health Inc. Freenome Inc. early cancer detection liquid biopsy earli delfi...
BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

...Assistant Editor Paige’s $100 million series C suggests investor enthusiasm for cancer diagnostics extends beyond liquid biopsy...
...versus normal cells.The large venture rounds come after several high-profile M&A events and fund-raisings for liquid biopsy...
BioCentury | Jan 12, 2021
Deals

Jan. 11 Quick Takes: Inmagene gains options to four Chi-Med immunology programs; plus Zai-Turning Point, Mirati-Resolution, GSK-Eligo, Biogen-Apple, Adaptive-AZ and more

...to Turning Point’s lead program repotrectinib for the same up front sum.Mirati to use Resolution’s liquid biopsy...
...patientsMirati Therapeutics Inc. (NASDAQ:MRTX) said it partnered with Resolution Bioscience Inc. to use its ctDx liquid biopsy...
BioCentury | Nov 19, 2020
Management Tracks

CStone’s Yeh joins Abbisko as CFO; plus moves at Ziopharm, Permira, Imara, Inivata, Topas and Arch

...global head of cystic fibrosis regulatory strategy and commercial regulatory affairs at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX).Liquid biopsy...
BioCentury | Nov 18, 2020
Emerging Company Profile

InterVenn: liquid biopsy diagnostics based on glycoproteins

...to launch its first diagnostic —a liquid biopsy...
...approaches.InterVenn hasn’t had to compete with DNA-based liquid biopsy...
...reported interim data from VOCAL showing the liquid biopsy...
BioCentury | Nov 10, 2020
Regulation

Label expansions coming at a rapid clip for Foundation’s blood-based companion cancer diagnostic

...three weeks, FDA has added four companion diagnostic indications to the label of Foundation Medicine’s liquid biopsy...
BioCentury | Oct 28, 2020
Deals

Thrive takeout could herald consolidation trend for early cancer detection companies

...24, its shares rose 27% to $94.04  after a presentation revealed it was developing its own liquid biopsy...
BioCentury | Oct 8, 2020
Product Development

Mapping opportunities for China’s early cancer detection boom

...willingness to pay out of pocket. At least three Chinese companies have already begun offering liquid biopsy...
...healthcare expenditure,” Decheng Capital’s Victor Tong told BioCentury.The country set a precedent for adoption of liquid biopsy-based...
...these companies are now branching into early detection.One of the first Asian companies built around liquid biopsy...
Items per page:
1 - 10 of 185